Breast cancer molecular subtyping (luminal A, luminal B, HER2-enriched, and triple-negative) guides systemic therapy selection and prognostication, yet is still determined primarily by invasive tissue sampling. This evidence concerns the gene ERBB2 and breast carcinoma.